1. Home
  2. ABCL vs MQ Comparison

ABCL vs MQ Comparison

Compare ABCL & MQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$7.87

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Marqeta Inc.

MQ

Marqeta Inc.

HOLD

Current Price

$4.09

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABCL
MQ
Founded
2012
2010
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
ABCL
MQ
Price
$7.87
$4.09
Analyst Decision
Strong Buy
Hold
Analyst Count
5
10
Target Price
$8.40
$5.36
AVG Volume (30 Days)
7.1M
5.1M
Earning Date
05-11-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
10.91
N/A
EPS
N/A
N/A
Revenue
$75,128,000.00
$624,884,000.00
Revenue This Year
N/A
$16.89
Revenue Next Year
$21.85
$16.36
P/E Ratio
N/A
N/A
Revenue Growth
160.56
23.25
52 Week Low
$2.75
$3.70
52 Week High
$8.42
$7.04

Technical Indicators

Market Signals
Indicator
ABCL
MQ
Relative Strength Index (RSI) 73.27 54.10
Support Level $3.32 $3.80
Resistance Level N/A $4.14
Average True Range (ATR) 0.53 0.15
MACD 0.24 0.04
Stochastic Oscillator 83.58 59.84

Price Performance

Historical Comparison
ABCL
MQ

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

About MQ Marqeta Inc.

Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.

Share on Social Networks: